AACR: Pfizer and Lilly CDK 4/6 inhibitors show breast cancer promise
This article was originally published in Scrip
Executive Summary
Two investigational drugs acting on the cyclin-dependent kinase pathway have shown promising results at the American Association for Cancer Research (ACCR) meeting in San Diego, this week: Pfizer's palbociclib, and Eli Lilly's follower LY2835219.